NCT01844726

Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Northwestern University · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.

Detailed description

In a single blind randomized parallel group design, we will evaluate the whether a single dose of GLYX-13 vs. placebo increases cognitive performance on tasks of learning, declarative memory, and working memory, and associated task-related increases in blood oxygen level-dependent (BOLD) activation in hippocampus and dorsolateral prefrontal cortex, respectively. Positive findings will provide biomarker evidence for GLYX-13 effects on neural systems underlying these cognitive processes.

Conditions

• Psychiatric Illness
• Healthy

Interventions

Type	Name	Description
DRUG	GLYX-13	Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
DRUG	Placebo	Single injection of placebo (saline)

Timeline

• Start date: 2013-05-01
• Primary completion: 2016-01-01
• Completion: 2016-01-01
• First posted: 2013-05-01
• Last updated: 2023-04-20
• Results posted: 2023-04-20

Locations

1 site across 1 country: United States